Filter posts

BIO Testifies at 21st Century Cures Hearing on PCAST

Today, BIO’s Executive Vice President of Health Sara Radcliffe presented testimony to the U.S. House …

Driving Innovation through Federal Investments

Today, BIO submitted testimony to the Senate Committee on Appropriations on the importance of driving …

NIH & NSF SBIR/STTR Programs

Leveraging Small Business to Bring Life-Saving Innovations to the Market. A key part of the …

U.S. Rep. Charlie Dent Discusses PDUFA and NIH Funding at #BIOCEO14

During the 16th Annual BIO CEO & Investor Conference, U.S. Representative Charlie Dent of Pennsylvania, …

Congress Passes Omnibus Spending Agreement

This week, BIO President and CEO Jim Greenwood praised the Congress for passing the fundingbill …

SBIR Reauthorization Moves Forward

NIH has reissued its Small Business Innovation Research (SBIR) Omnibus Grant Solicitation announcement, which states …

Legislative Hopes, Fears

Biotechnology advances are poised now more than ever to help policymakers achieve their goals of …

Simpson Bowles Keynote to Address Debt, Taxes, Government Services and Politics

I was recently asked what the single biggest threat to the biotechnology industry is today.  …

Public Health at Risk: Don’t Cut Programs that Work

In order to avoid the “fiscal cliff,” the Congress must compromise and protect our economic …

Research: Working Together Toward Cures

Modern biomedical innovation and the discovery of new cures and therapies for devastating diseases require …